Nykredit A S Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Nykredit A/S initiated a Regeneron Pharmaceuticals position in the second quarter, purchasing 38,439 shares valued at approximately $24 million. Institutional investors and hedge funds collectively own 83.31% of REGN.
• Regeneron reported strong quarterly results, with earnings of $14.29 per share and revenue of $4.29 billion, exceeding analyst expectations; revenue increased 16.7% year over year.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $802.18. The company also pays a quarterly dividend of $0.94, while insiders have recently sold shares under pre-arranged trading plans.

Nykredit A S bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 38,439 shares of the biopharmaceutical company's stock, valued at approximately $23,968,000.

Several other institutional investors and hedge funds have also modified their holdings of REGN. Western Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $26,000. SHP Wealth Management acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $26,000. Titan Wealth CI Ltd acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth approximately $29,000. MCF Advisors LLC increased its stake in Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company's stock worth $35,000 after acquiring an additional 15 shares during the period. Finally, Mowery & Schoenfeld Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $29,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $784.85 on Friday. The company's 50 day moving average price is $766.83 and its two-hundred day moving average price is $720.73. The firm has a market capitalization of $80.81 billion, a P/E ratio of 19.40, a P/E/G ratio of 1.54 and a beta of 0.20. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $859.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts' consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company had revenue of $4.29 billion during the quarter, compared to analysts' expectations of $3.82 billion. During the same period in the prior year, the company earned $12.81 EPS. Regeneron Pharmaceuticals's revenue was up 16.7% compared to the same quarter last year. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were paid a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals's dividend payout ratio is currently 9.29%.

Analyst Ratings Changes

A number of analysts have recently weighed in on REGN shares. Benchmark upgraded Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $185.00 target price for the company in a research report on Tuesday, July 7th. Weiss Ratings restated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Citigroup boosted their price target on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a "neutral" rating in a research note on Monday, August 3rd. Piper Sandler cut their price objective on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating for the company in a research report on Thursday, July 9th. Finally, Guggenheim increased their price objective on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the stock a "buy" rating in a research note on Monday, August 3rd. Fourteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $802.18.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Kathryn Guarini sold 400 shares of the firm's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the transaction, the director owned 603 shares of the company's stock, valued at approximately $512,550. This trade represents a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $1,032,750.00. Following the transaction, the executive vice president directly owned 13,134 shares in the company, valued at $11,163,900. The trade was a 8.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 4,146 shares of company stock worth $3,432,488. 6.97% of the stock is owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron's marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.